Haixiang Pharmaceutical announced that the phase II clinical trial of China's first off-the-shelf cancer therapeutic vaccine, NWRD08 injection, independently developed by the participating company Novell's Biotech was officially launched in Beijing Union Medical College Hospital and other hospitals, and the enrollment and administration of the first test subjects has been completed.

Haixiang Pharmaceutical announced that the phase II clinical trial of China's first off-the-shelf cancer therapeutic vaccine, NWRD08 injection, independently developed by the participating company Novell's Biotech was officially launched in Beijing Union Medical College Hospital and other hospitals, and the enrollment and administration of the first test subjects has been completed.